

## Grifols names new senior executives

- *Dr. Roland Wandeler becomes President of the company's Biopharma Business Unit, and Camille Alpi assumes the role of Chief Human Resources and Talent Officer*
- *Both have longstanding international experience in their respective areas and reinforce a senior leadership team whose recent appointments include Jörg Schüttrumpf, Chief Scientific Innovation Officer, and Miguel Louzan, Chief Digital Information Officer*

**Barcelona, Spain, Feb. 1, 2024** – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has served patients and society for 115 years, today announced it has reinforced its senior management team with two appointments. Roland Wandeler, Ph.D., is the new President of its Biopharma Business Unit, while Camille Alpi begins as Chief Human Resources and Talent Officer.

Dr. Wandeler brings more than two decades of global biopharmaceutical experience to Grifols. He has a track record of driving commercial, operational and organizational excellence throughout his career in both Europe and the United States. This includes being Chief Commercial Officer at MorphoSys, where he helped build a fully integrated biopharmaceutical company. Prior to that, Mr. Wandeler worked for 14 years at Amgen, where he held executive positions of increasing responsibility, including Corporate Vice President and General Manager Bone Health and Cardiology in the U.S., a multibillion growth business. He replaces Joel Abelson, who is retiring.

Dr. Wandeler is a graduate of the Swiss Federal Institute of Technology (ETH), in Zurich. He holds a doctorate in technical sciences as well as Master of Science in chemical engineering. He is located in Grifols' corporate offices in North Carolina's Research Triangle Park, not far from the company's flagship plasma-medicines manufacturing site in Clayton, N.C.

Mr. Alpi is an international HR executive with 20 years of experience across Europe, the U.S., South America and Asia. Prior to coming to Grifols, he was Vice President Human Resources for Danone Specialized Nutrition, the company's healthcare division. Here he drove HR initiatives at the local, regional and global levels, focusing on talent and organizational development, employee experience and engagement, as well as transformation and change management.

Mr. Alpi has a master's degree in business and economics from Uppsala University, Sweden. He is based in the company's global headquarters, in Sant Cugat (Barcelona), and takes over from Montse Gaja, who has decided to retire.

Following handovers from their predecessors, Dr. Wandeler and Mr. Alpi report to Víctor Grifols Deu, Chief Operating Officer. "We are delighted to welcome both Camille and Roland to Grifols, where we continue to build a world-class, talented executive team," said Mr. Grifols Deu. "Their broad international experience in their respective areas of expertise will contribute greatly to our leadership in providing more medicines to more patients in more parts of the world."

# GRIFOLS

“I am honored to be joining the team at Grifols, a pioneer and leader in essential plasma-derived therapies, and a prestigious name in healthcare that stands for high quality trusted medicines,” said Mr. Wandeler. “Throughout my career, in markets around the world, I have been passionate about building and leading diverse, high-performing teams and driving innovation for patients. With its portfolio of life-changing medicines across a wide range of therapeutic areas, Grifols is uniquely positioned to make a difference for patients, true to their mission to enable people to lead better-quality lives.”

“This is as an exciting time as ever to become part of Grifols, a preeminent organization thoroughly committed to strengthening and building its motivated performance-driven culture to provide lifesaving medicines and solutions to patients,” stated Mr. Alpi. “I look forward to leading this company’s progressive forward-thinking HR function and doing what I can to make Grifols an even more attractive workplace for inspired people who want a lasting career making a positive impact in the health and quality of life of individuals.”

The new appointments round out an enhanced senior leadership team whose recent additions include Jörg Schüttrumpf as Chief Scientific Innovation Officer and Miguel Louzan, Chief Digital Information Officer.

## **MEDIA CONTACT:**

### **Grifols Press Office**

[media@grifols.com](mailto:media@grifols.com)

Tel. +34 93 571 00 02

### **Investor contact:**

### **Investor Relations**

[inversores@grifols.com](mailto:inversores@grifols.com) - [investors@grifols.com](mailto:investors@grifols.com)

Tel.: +34 93 571 02 21

## **About Grifols**

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and our ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world’s largest with over 390 across North America, Europe, Africa and the Middle East and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. We provide high-quality biological supplies for life-science research, clinical trials, and for manufacturing

# GRIFOLS

pharmaceutical and diagnostic products. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

In 2022, Grifols' economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit [grifols.com](https://www.grifols.com)

## **LEGAL DISCLAIMER**

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.